Browse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about GlobalPharmacyMeds.to
List of countries where we can ship Rimonabant:
Latest news releases on Rimonabant:
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn ...
Sanofi-Aventis has withdrawn rimonabant from the market globally and it is no longer under development. 1 Acomplia was officially withdrawn by the European Medicines ...
Atrial fibrillation has been attributed to rimonabant in two cases [114 A]. • A man who took rimonabant for 5 weeks developed palpitation, fatigue, and exertional ...
Rimonabant is a pyrazole and piperidine derivative that acts as a selective cannabinoid type-1 receptor (CB1 RECEPTOR) antagonist. It inhibits the proliferation and ...
European Union agency responsible for the protection of public and animal health through the scientific evaluation and supervision of medicines.
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works...Read More...
Le rimonabant (ou SR141716) est un médicament anorexigène contre l'obésité agissant comme un agoniste inverse des récepteurs cannabinoïdes CB1.
Rimonabant (conocido también como SR141716), [n 1] es un inhibidor del apetito que actualmente se encuentra fuera del mercado en gran parte del mundo.
Rimonabant ist ein Arzneistoff, der als Appetitzügler zur Behandlung des Übergewichts eingesetzt wurde, eigentlich allerdings zur Raucherentwöhnung von dem ...
RESULTS: Clinical trials have revealed that rimonabant may promote weight loss in obese patients, although it may also induce symptoms of anxiety and depression.